Participating Companies

Advicenne [ADVIC:PA] €59 MM MCap
Ad­vi­cenne is a spe­cial­ty phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to pa­tients suf­fer­ing from rare and ne­glect­ed dis­eas­es. Ad­vi­cenne is com­mitt­ed to de­vel­op­ing and com­mer­cial­iz­ing med­i­ca­tions that are adapt­ed to both chil­dren and adults be­cause path­break­ing treat­ments for rare dis­eas­es should be avai­l­able to pa­tients of all ages. [more in­for­ma­tion]
Avacta [AVCT:LN] £297 MM MCap
UK-based com­pany de­vel­op­ing pro­pri­e­tary next-gen anti­bodies called Af­fimers. Avac­ta is a new Trout client that is a bit un­der the ra­dar with limit­ed US-ex­po­sure to date. They are a bit small/ear­ly but we have been gett­ing in­ter­est so far on their ap­proach – sim­i­lar con­cept to Ab­l­ynx, part­n­er­ship with Mod­er­na, etc. Af­fimers are 10X small­er than tra­di­tio­n­al anti­bodies that are easy to for­mat, high­ly spe­cif­ic, easy to man­u­fac­ture, mul­ti­ple routes of ad­min­is­tra­tion, etc. – com­para­ble to Ab­l­ynx’s nan [more in­for­ma­tion]
BioNTech AG [BNTX] US$15,956 MM MCap
Through its di­ver­si­fied tech­nol­o­gy plat­forms and in-house di­ag­nos­tics and man­u­fac­tur­ing units, BioN­Tech is strate­g­i­cal­ly po­si­tioned to im­ple­ment its lab-bench-to-mar­ket strat­e­gy. [more in­for­ma­tion]
BioPorto [CPH: BIOPOR]
Bio­Por­to Di­ag­nos­tics A/S is an in-vit­ro di­ag­nos­tics com­pany that pro­vides health­care pro­fes­sio­n­als in clin­i­cal and re­search sett­ings a range of di­ag­nos­tic tests and anti­bodies. With key ex­per­tise in bio­mark­er de­tec­tion, Bio­Por­to has a deep port­fo­lio of di­ag­nos­tic aides for the re­search sett­ing. [more in­for­ma­tion]
Bone Therapeutics SA [BT1:FF] €25 MM MCap
Bone Ther­a­peu­tics is a biotech­nol­o­gy com­pany with a unique ap­proach to the de­vel­op­ment of cell ther­a­py prod­ucts for bone frac­ture re­pair and frac­ture pre­ven­tion. Bone Ther­a­peu­tics' tech­nol­o­gy is based on a unique, pro­pri­e­tary ap­proach to bone re­gen­er­a­tion which turns un­d­if­fer­en­ti­at­ed stem cells in­to “os­teoblas­tic”, or bone-form­ing cells. [more in­for­ma­tion]
Cellectis SA [CLLS] US$719 MM MCap
By cap­i­tal­iz­ing on its 19 years of ex­per­tise in gene edit­ing – built on its flag­ship TAL­EN® tech­nol­o­gy and pi­oneer­ing elec­tro­po­ra­tion sys­tem PulseAg­ile – Cel­lec­tis us­es the pow­er of the im­mune sys­tem to tar­get and erad­i­cate can­cer cells. [more in­for­ma­tion]
Chronos Therapeutics
Chronos has a bal­anced port­fo­lio of pre-IND pro­grammes in ad­dic­tion (orexin-1 an­ta­g­on­ist, ini­tial­ly in binge eat­ing di­s­or­der with util­i­ty in al­co­hol use di­s­or­der, anxi­e­ty and other com­pul­sive di­s­or­ders), fa­tigue (atyp­i­cal do­pamine ac­tive tran­s­porter in­hibi­tor ini­tial­ly in MS fa­tigue but with util­i­ty in other cen­tral fa­tigue di­s­or­ders) and a re-pur­posed as­set in ALS. [more in­for­ma­tion]
Curetis AG [CURE:AS] €6 MM MCap
Curetis’ Un­yvero Sys­tem is a ver­satile, fast and high­ly au­to­mat­ed molec­u­lar di­ag­nos­tic plat­form for easy-to-use, car­tridge-based so­lu­tions for the com­pre­hen­sive and rapid de­tec­tion of patho­gens and an­timi­cro­bial re­sis­tance mark­ers in a range of se­vere in­fec­tious dis­ease in­di­ca­tions. [more in­for­ma­tion]
Heidelberg Pharma AG [HPHA:DB] €139 MM MCap
Hei­del­berg Phar­ma AG (WL6, Frank­furt Stock Exchange), based in La­den­burg, Ger­many, is a lead­ing biotech com­pany pi­oneer­ing the use of its AT­AC (Anti­body Tar­get­ed Amanitin Con­ju­gate) plat­form to de­vel­op nov­el can­cer treat­ments with a unique mode of ac­tion ef­fec­tive at spe­cif­i­cal­ly killing both in­ac­tive and di­vid­ing can­cers cells and over­com­ing tu­mour re­sis­tance mech­anisms. [more in­for­ma­tion]
Immunicum AB [IMMU:ST] SKr858 MM MCap
Im­mu­nicum is estab­lish­ing a unique im­muno-on­col­o­gy ap­proach through the de­vel­op­ment of al­lo­gene­ic, off-the-shelf cell-based ther­a­pies. Im­mu­nicum's goal is to im­prove sur­vi­val out­comes and qual­i­ty of life by prim­ing the pa­tient’s own im­mune sys­tem to fight can­cer. [more in­for­ma­tion]
Medigene AG [MDG1:DB] €139 MM MCap
blue­bird bio col­lab; BLUE ini­ti­at­ing trial w/MDG MAGEA-4 can­di­date in 2020. TCRs tar­get­ing HA-1 & MAGE-A1 in de­vt. . DC vax in on­go­ing Ph 1/2; fi­nal read­out in 2019. [more in­for­ma­tion]
Medivir AB [MVIR B:ST] SKr936 MM MCap
Nu­cleotide-pro­drug plat­form: MIV-818, an oral pro­drug of the clin­i­cal­ly ef­fec­tive troxac­itabine, for HCC and MIV-828 for AML. Ad­vanced clin­i­cal pro­grams for part­ner­ing: Birini­pant, a bi­va­lent SMAC mimet­ic; Remeti­no­s­tat for CT­CL and Ph 3 ready MIV-711 for OA. [more in­for­ma­tion]
Nanobiotix SA [NANO:PA] €158 MM MCap
Nano­bi­otix is a lead­ing, clin­i­cal-stage nanomedicine com­pany pi­oneer­ing new ap­proach­es to sig­ni­f­i­cant­ly change pa­tient out­comes by bring­ing nano­physics to the heart of the cell. Nano­bi­otix’s Im­muno-On­col­o­gy pro­gram has the po­ten­tial to bring a new di­men­sion to can­cer im­munother­a­pies. [more in­for­ma­tion]
Novaremed AG
No­varemed has suc­cess­ful­ly com­plet­ed a Phase IIa (PoC) study show­ing clin­i­cal­ly rel­e­vant re­duc­tion in pa­tient re­port­ed pain. No­varemed is cur­rent­ly pre­par­ing to conduct a glob­al Phase IIb study in DNP ex­pect­ed to start in Q1 2020. [more in­for­ma­tion]
Oncimmune [ONC:LN] £79 MM MCap
Oncim­mune's pro­pri­e­tary plat­form is un­der­pinned by rapid bio­mark­er dis­cov­ery and a com­pre­hen­sive im­muno­genic pro­tein li­brary of over 8,000 anti­genic pro­teins. [more in­for­ma­tion]
Photocure ASA [PHO:OS] NKr1,931 MM MCap
Pho­to­cure is a rev­enue-gen­er­at­ing com­mer­cial stage com­pany fo­cused on urol­o­gy. Lead prod­uct Hexvix/Cysview is an op­ti­cal imag­ing agent for im­proved de­tec­tion, re­duced dis­ease re­cur­rence and pro­gres­sion rates of blad­der can­cer. [more in­for­ma­tion]
Rexgenero Ltd.
The com­pany’s lead can­di­date, REX-001, is a high­ly in­no­va­tive au­tol­o­gous cell ther­a­py that is be­ing studied in a Phase III clin­i­cal pro­gram in pa­tients with crit­i­cal limb is­chemia (CLI) with di­a­betes, a poor­ly treat­ed dis­ease with a high risk of am­pu­ta­tion and death. [more in­for­ma­tion]
Sensorion [ALSEN:PA] €52 MM MCap
Sen­so­ri­on is a clin­i­cal-stage biotech and gene ther­a­py com­pany that spe­cial­izes in the de­vel­op­ment of nov­el ther­a­pies to re­s­tore, treat and pre­vent within the field of hear­ing loss di­s­or­ders. SENS-401 is in a Phase 2 clin­i­cal trial as a treat­ment for sud­den sen­sorineu­ral hear­ing loss. [more in­for­ma­tion]
sterna biologicals
By tar­get­ing tran­scrip­tion fac­tors that play a cen­tral role in reg­u­lat­ing Th1- and Th2-driv­en in­flam­ma­to­ry mech­anisms, the Com­pany’s pro­pri­e­tary DNAzyme-based drug can­di­dates can in­ter­vene with up­stream in­flam­ma­to­ry pro­cess­es to ad­dress re­lat­ed dis­eas­es more ef­fec­tive­ly. Ster­na cur­rent­ly has four pro­grams in phase 2 de­vel­op­ment. [more in­for­ma­tion]
Targovax [TRVX:OS] NKr497 MM MCap
Pre­lim­i­nary Ph1b da­ta of OV ON­COS-102+che­mo in me­sothe­lio­ma re­sults: com­bo mPFS=8.4 mos. vs. con­trol mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Up­com­ing mile­s­tones: up­dat­ed clin­i­cal & im­mune da­ta in Ph2 me­sothe­lio­ma (1H20); pre­clin­i­cal da­ta on next-gen OV w/ dou­ble trans­genes (1H20); and clin­i­cal da­ta from Ph1 me­lano­ma study, part 2 with ex­tend­ed dos­ing (2H20). [more in­for­ma­tion]
Viramal Limited
Vi­ra­mal is an emerg­ing spe­cial­ty phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment of glob­al ther­a­peu­tics that im­prove the qual­i­ty of wo­m­en’s health world­wide. The com­pany is de­vel­op­ing in­no­va­tive prod­ucts that tar­get un­met ther­a­peu­tic ar­eas through the use of its unique phar­ma­ceu­ti­cal de­liv­ery plat­forms and tech­nolo­gies. [more in­for­ma­tion]
Vivoryon [PRBGF] US$119 MM MCap
Vivo­ry­on's pro­grams are based on ded­i­cat­ed re­search, top-lev­el dis­cov­ery and de­ter­mined de­vel­op­ment. The com­pany de­vel­ops first-in-class medicines that tar­get post-trans­la­tio­n­al mod­i­fy­ing en­zymes. The pipe­line con­tains sev­er­al prod­uct can­di­dates across vari­ous stages of de­vel­op­ment, fo­cused on Alzheimer’s Dis­ease and on­col­o­gy. [more in­for­ma­tion]